Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GRIOTCMKTS:MINECVE:NVVNASDAQ:PBM On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGRIGRI Bio$1.44-0.7%$1.46$1.10▼$43.69$3.08M-1.62107,067 shs80,311 shsMINEMinerco$0.00$0.00▼$0.00N/AN/A385,000 shsN/ANVVNorvista CapitalC$0.08-6.3%C$0.08C$0.07▼C$0.23C$5.26MN/A116,000 shs112,500 shsPBMPsyence Biomedical$5.38-4.8%$4.71$2.92▼$699.19$2.96M0.22113,340 shs28,644 shs7 Stocks to Buy And Hold ForeverEnter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising. Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGRIGRI Bio0.00%+13.39%-0.69%-4.64%-94.71%MINEMinercoNaNNaNNaNNaNNaNNVVNorvista Capital0.00%0.00%0.00%0.00%0.00%PBMPsyence Biomedical0.00%+8.49%-1.81%+46.14%-97.02%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGRIGRI Bio3.4557 of 5 stars3.55.00.00.03.20.01.3MINEMinercoN/AN/AN/AN/AN/AN/AN/AN/ANVVNorvista CapitalN/AN/AN/AN/AN/AN/AN/AN/APBMPsyence BiomedicalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGRIGRI Bio 3.00Buy$22.001,427.78% UpsideMINEMinerco 0.00N/AN/AN/ANVVNorvista Capital 0.00N/AN/AN/APBMPsyence Biomedical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest MINE, NVV, PBM, and GRI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/11/2025GRIGRI BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy5/27/2025GRIGRI BioAscendiant Capital MarketsSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$40.00 ➝ $34.004/14/2025GRIGRI BioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$10.00 ➝ $10.00(Data available from 7/5/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGRIGRI BioN/AN/AN/AN/A$7.68 per shareN/AMINEMinercoN/AN/AN/AN/AN/AN/ANVVNorvista Capital-C$1.27M-4.13C$0.12 per share0.63C$0.11 per share0.67PBMPsyence BiomedicalN/AN/A$1.85 per share2.91$11.80 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGRIGRI Bio-$8.21M-$11.56N/AN/AN/AN/A-275.15%-168.22%8/12/2025 (Estimated)MINEMinercoN/A-$0.01N/AN/AN/AN/AN/AN/AN/ANVVNorvista CapitalN/A-C$0.05N/A∞N/AN/AN/AN/AN/APBMPsyence Biomedical$1.01MN/A0.00∞N/AN/AN/AN/AN/ALatest MINE, NVV, PBM, and GRI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025GRIGRI Bio-$4.08-$5.80-$1.72-$5.80N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGRIGRI BioN/AN/AN/AN/AN/AMINEMinercoN/AN/AN/AN/AN/ANVVNorvista CapitalN/AN/AN/AN/AN/APBMPsyence BiomedicalN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGRIGRI BioN/A1.411.41MINEMinercoN/AN/AN/ANVVNorvista Capital0.0711.6211.58PBMPsyence BiomedicalN/A11.0411.04Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGRIGRI Bio33.95%MINEMinerco0.01%NVVNorvista CapitalN/APBMPsyence Biomedical77.44%Insider OwnershipCompanyInsider OwnershipGRIGRI Bio0.13%MINEMinerco1.72%NVVNorvista CapitalN/APBMPsyence Biomedical3.60%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGRIGRI Bio12.14 million2.14 millionNot OptionableMINEMinerco28N/AN/ANot OptionableNVVNorvista Capital1,99070.14 millionN/ANot OptionablePBMPsyence BiomedicalN/A570,000548,000N/AMINE, NVV, PBM, and GRI HeadlinesRecent News About These CompaniesPSYENCE GROUP INC. Announces Update on Previously Announced Non-Brokered Private Placement of Common SharesJune 25, 2025 | globenewswire.comPsyence Biomedical regains Nasdaq compliance after reverse splitJune 18, 2025 | investing.comPSYENCE GROUP INC. Announces Offering of up to C$600,000 Non-Brokered Private Placement of Common SharesJune 18, 2025 | globenewswire.comPsyence BioMed Chief of Global Impact to Speak at Psychedelic Science 2025June 18, 2025 | newsfilecorp.comNPsyence Biomedical Ltd.: Psyence Biomed Regains Full Compliance with NASDAQ Continued Listing RequirementsJune 17, 2025 | finanznachrichten.dePsyence Biomed Regains Full Compliance with NASDAQ Continued Listing RequirementsJune 17, 2025 | newsfilecorp.comNCVS Sues Arkansas Over Law Banning PBM Ownership Of PharmaciesMay 29, 2025 | forbes.comPsyence BioMed Finalizes Agreement with Award-Winning CRO Southern Star Research to Accelerate Phase IIb Clinical TrialMay 27, 2025 | newsfilecorp.comNPsyence Biomedical Ltd. WtMay 21, 2025 | marketwatch.comPsyence Biomedical Advances Psilocybin Drug Development as of May 2025May 20, 2025 | tipranks.comPsyence Biomedical announces reverse stock splitMay 2, 2025 | investing.comPsyence BioMed Announces Effective Date for 1-for-7.97 Reverse Stock SplitMay 1, 2025 | newsfilecorp.comNPsyence Group consolidates its sharesApril 18, 2025 | greenmarketreport.comGPsyence BioMed gets Nasdaq notice for non-complianceApril 18, 2025 | msn.comPsyence BioMed Receives Nasdaq Notification Regarding Minimum Bid Price DeficiencyApril 17, 2025 | newsfilecorp.comNPsyence Group Inc.: Psyence Group Announces Share ConsolidationApril 17, 2025 | finanznachrichten.dePsyence Group Announces Share ConsolidationApril 17, 2025 | globenewswire.comPsyence BioMed invests $500,000 more into PsyLabs, locks down Ibogaine supply dealApril 16, 2025 | greenmarketreport.comGPsyence BioMed Announces USD$500,000 Follow-On Investment in PsyLabs and Global Ibogaine Supply AgreementApril 15, 2025 | newsfilecorp.comNPsyence BioMed Signs LOI with Southern Star Research to Expand Phase IIb Clinical Trial in AustraliaApril 8, 2025 | newsfilecorp.comNNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir SoonIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI DefenseIntel's Turnaround Strategy Shifts From Planning to Attack ModeBy Jeffrey Neal Johnson | June 20, 2025View Intel's Turnaround Strategy Shifts From Planning to Attack ModeValue vs Growth Ratio Hits Cycle Low—Top Value Picks to BuyBy Gabriel Osorio-Mazilli | June 30, 2025View Value vs Growth Ratio Hits Cycle Low—Top Value Picks to BuyMINE, NVV, PBM, and GRI Company DescriptionsGRI Bio NASDAQ:GRI$1.44 -0.01 (-0.69%) As of 07/3/2025 01:00 PM EasternGRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on treating inflammatory, fibrotic, and autoimmune diseases in the United States. Its product pipeline comprises GRI-0621, which is in phase II clinical development for the treatment of idiopathic pulmonary fibrosis; GRI-0803 which is in phase I trial for the treatment of systematic lupus erythematosus; GRI-0124, which is in pre-clinical development for the treatment of primary sclerosing cholangitis; and GRI-0729 in pre-clinical development. The company also develops ADAIR and ADMIR for treatment of attention -deficit/hyperactivity disorder. GRI Bio, Inc. was formerly known as Glycoregimmune, Inc. GRI Bio, Inc. was founded in 2009 and is based in LA Jolla, California.Minerco OTCMKTS:MINEMinerco, Inc. is a holding company, which engages in brand management which specializes in the development of beverage, entertainment, and related ancillary brands. Its brands include VitaminFIZZ and The Herbal Collection. The company was founded on June 21, 2007 and is headquartered in May Pen, Jamaica.Norvista Capital CVE:NVVC$0.08 -0.01 (-6.25%) As of 01/12/2022Norvista Capital Corporation operates as a resource investment company and merchant bank in the United States and Canada. It invests in a portfolio of companies that are involved in the exploration of base and precious metals, such as copper, zinc, silver, gold, and lead, as well as oil and gas located in Chile, Manitoba, Yukon, Mexico, and Nevada; and oil and gas in Israel, the United States, Brazil, and Canada. The company was founded in 2014 and is headquartered in Toronto, Canada.Psyence Biomedical NASDAQ:PBM$5.38 -0.27 (-4.76%) Closing price 07/3/2025 03:58 PM EasternExtended Trading$5.41 +0.03 (+0.61%) As of 07/3/2025 04:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Psyence Biomedical Ltd. engages in the development of botanical psilocybin-based psychedelic medicines. It also evaluates natural psilocybin for the treatment of adjustment disorder in patients with an incurable cancer diagnosis in a palliative care context. The company's lead product candidate is PEX010, which is in Phase IIb clinical study, a capsule containing naturally sourced psilocybin for treatment of anxiety and depression, including associated ailments, such as post-traumatic stress disorder, stress, grief, and adjustment disorder in the context of palliative care. It has a partnership with iNGENu Pty Ltd to conduct a Phase IIb clinical trial of PEX010 in psilocybin-assisted psychotherapy for the treatment of AjD due to incurable cancer. The company is based in Toronto, Canada. Psyence Biomedical Ltd. operates as a subsidiary of Psyence Group Inc. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas The Apple Comeback Will Be Better Than the Setback Micron’s Big Q3 Drives Applied Materials’ Bullish Outlook Why Occidental's Price Dip Signals a Buying Opportunity Qualcomm’s Hold Rating Misses Strong Growth Story Rigetti Computing: Cantor's Bullish Call May Be Just the Start Insider Selling at NVIDIA Could Turn Into an Opportunity Whiplash for Investors: AeroVironment's Confusing Stock Signals Rocket Lab: Latest Catalysts Bolster the Bull Case Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
